Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,664 across all filing types
Latest filing 2024-07-21 Capital/Financing Update
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 589.5KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Anteris Technologies Ltd regarding a trading halt requested pending an announcement about a proposed capital raising. It references ASX Listing Rule 17.1 and states the halt will remain until an announcement about the capital raising outcome or normal trading resumes. The document is short (2193 characters) and does not contain any financial data or detailed report content. It is an announcement about a trading halt related to capital raising, not the capital raising update itself. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes.
2024-07-21 English
Anteris and v2vmedtech Announce Concept Lock for VClip 2 pages 195.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 1 July 2024, describing a product development milestone for Anteris Technologies Ltd and v2vmedtech. It discusses the concept lock of a new medical device system (VClip[TM]) and provides background on the company and its products. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a corporate announcement about product development progress, not a financial report, regulatory filing, or meeting material. It is relatively short (4239 characters) and does not mention any report being attached or published. Therefore, it fits best as a general regulatory announcement about company progress and product development, which falls under Regulatory Filings (RNS).
2024-06-30 English
Notification regarding unquoted securities - AVR 8 pages 22.0KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of options to directors as approved by shareholders at the AGM held on 29 May 2024. It includes specifics about the securities issued, their terms, and the purpose of the issue (director remuneration). The document is a formal notification of a share issue event, specifically unquoted equity securities (options). It is not a full financial report, earnings release, or management discussion. It is an announcement about a capital change related to securities issuance. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (7975 characters) and detailed content support this classification with high confidence.
2024-06-24 English
Change of Director's Interest Notice 11 pages 368.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed disclosures of changes in securities holdings by company directors, including the number of shares and options held before and after the change, dates of changes, and nature of the changes. It references ASX listing rules and the Corporations Act, indicating it is a regulatory filing related to insider transactions. The content is focused on directors' personal share transactions and interests, consistent with insider trading disclosures. There is no indication of financial results, management commentary, or other report types. The document is not an announcement of a report but a detailed notice itself. Therefore, the appropriate classification is Director's Dealing (DIRS).
2024-06-24 English
FIH Data Confirms Optimal Valve Positioning with ComASUR 2 pages 207.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 20 June 2024 from Anteris Technologies Ltd. It reports new clinical data from the DurAVR™ First-in-Human Study, specifically haemodynamic performance data of their transcatheter heart valve and delivery system. The content focuses on clinical trial results and product performance rather than financial results or regulatory filings. There is no indication that this is a full financial report, audit report, or earnings release. It is a corporate announcement about clinical study data, which fits best under Capital/Financing Update (CAP) as it relates to product development progress and market positioning, which is often relevant to investors and capital markets. It is not a report publication announcement or regulatory filing, as it contains substantive data and analysis. Therefore, the most appropriate classification is CAP with high confidence.
2024-06-19 English
Update on Pivotal Trial Submission 2 pages 218.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 18 June 2024 from Anteris Technologies Ltd providing an update on a pivotal clinical trial submission and feedback from the US FDA. It discusses study design elements, regulatory interactions, and next steps toward marketing approval. There are no financial statements, earnings data, or detailed financial analysis present. The document is a regulatory update on clinical trial progress and FDA feedback, not a financial report or detailed management discussion. It is also not a report publication announcement or certification. The content fits best under a general regulatory announcement category, as it provides important company and regulatory information but does not fit into more specific financial or governance report categories.
2024-06-17 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.